Is everyone in LA really on Ozempic? Separating hype from data

What did @listnrau actually say?

The hosts described Ozempic as "a diabetes drug" that celebrities and models are using to lose weight, claimed it "switches off your appetite" so users are "basically just not eating," and flagged an Australian national shortage caused by people who "don't even need it." They also admitted uncertainty about long-term effects. That last part? Actually fair.

The framing is classic pop-culture Ozempic coverage: partially correct, somewhat reductive, and missing the clinical mechanics that actually matter. The shortage claim is real and documented. The "switches off your appetite" summary is a dramatic oversimplification of how GLP-1 receptor agonists work. And calling it a pure quick fix glosses over what the research says about stopping the drug.

Does the science back this up?

Semaglutide (the active ingredient in Ozempic and Wegovy) does reduce appetite, but not like a light switch. It works by mimicking the GLP-1 hormone, slowing gastric emptying, signaling satiety to the brain, and modulating dopamine pathways linked to food reward. That is meaningfully different from "just not eating."

Wilding et al. (2021, New England Journal of Medicine) showed that semaglutide 2.4mg produced an average 14.9% body weight reduction over 68 weeks in adults with obesity, but participants were also on a calorie-reduced diet and exercise program. The drug does not replace eating regulation entirely. Lean mass loss is also a documented concern: a 2023 analysis by Aronne et al. noted that roughly one-third of weight lost on semaglutide can come from lean muscle mass, not just fat. That is the kind of nuance missing from "you just lose things away on it."

What did they get wrong (or right)?

They got the shortage right. The Therapeutic Goods Administration in Australia issued repeated warnings from 2022 onward about semaglutide supply disruptions, explicitly linked to off-label prescribing for weight loss in people without type 2 diabetes. That is a real public health problem that left insulin-dependent diabetic patients without access. Credit where it is due.

What they got wrong: calling it purely a "quick fix" is misleading. Knop et al. (2023, Lancet) found that patients who stopped semaglutide regained approximately two-thirds of their lost weight within a year. That is the opposite of a quick fix. It is a long-term medication commitment for most users. They also described it only as a "diabetes drug," which is outdated. Wegovy, a higher-dose semaglutide formulation, received FDA approval specifically for chronic weight management in 2021. These are related but distinct regulatory approvals.

What should you actually know?

GLP-1 receptor agonists are among the most studied weight-loss drugs in recent history, but they are not consequence-free. Common side effects include nausea, vomiting, and gastrointestinal distress. Rarer but serious risks include pancreatitis and, based on rodent studies, thyroid C-cell tumors, though this has not been confirmed in humans at prescribed doses per the FDA label.

The "I don't know what it does long term" admission from the hosts is actually the most honest thing said in this clip. Long-term cardiovascular data is improving: the SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) found semaglutide reduced major cardiovascular events in adults with obesity and established cardiovascular disease. But multi-decade safety data does not yet exist for this drug class at scale. Anyone using or considering these medications should do so under medical supervision, with realistic expectations about what stopping the drug means for weight maintenance.